Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 12891212)

1.

Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions.

Walker KL, Walsh DB, Goodney PP, Connell SA, Stone DH, Powell RJ, Rzucidlo EM.

BMC Cardiovasc Disord. 2014 Dec 11;14:184. doi: 10.1186/1471-2261-14-184.

2.

Effect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trials.

Zhang MD, Zhang YH, Zhu EJ, Qiao SB, Lv SZ, Zhao QM.

PLoS One. 2014 Oct 3;9(10):e109614. doi: 10.1371/journal.pone.0109614. eCollection 2014.

3.

The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.

Manoria PC, Chopra HK, Parashar SK, Dutta AL, Pinto B, Mullasari A, Prajapati S.

Indian Heart J. 2013 Dec;65(6):683-90. doi: 10.1016/j.ihj.2013.10.015. Epub 2013 Nov 25.

4.

Role of metabolic environment on nitric oxide mediated inhibition of neointimal hyperplasia in type 1 and type 2 diabetes.

Rodriguez MP, Emond ZM, Wang Z, Martinez J, Jiang Q, Kibbe MR.

Nitric Oxide. 2014 Jan 30;36:67-75. doi: 10.1016/j.niox.2013.12.005. Epub 2013 Dec 12.

5.

Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.

Lee HW, Lee HC, Kim BW, Yang MJ, Park JS, Oh JH, Choi JH, Cha KS, Hong TJ, Kim SP, Song S, Park JH.

Yonsei Med J. 2013 Nov;54(6):1313-20. doi: 10.3349/ymj.2013.54.6.1313.

6.

Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).

García-García HM, Garg S, Brugaletta S, Morocutti G, Ratner RE, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Nesto RW, Serruys PW; APPROACH study group.

Int J Cardiovasc Imaging. 2012 Mar;28(3):455-65. doi: 10.1007/s10554-011-9836-z. Epub 2011 Feb 27.

7.
8.

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL.

Arch Intern Med. 2008 Oct 27;168(19):2070-80. doi: 10.1001/archinte.168.19.2070. Review.

10.

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

Dorkhan M, Frid A.

Vasc Health Risk Manag. 2007;3(5):721-31. Review.

11.

PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B.

Vasc Health Risk Manag. 2007;3(4):355-70. Review.

12.

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE.

Br J Pharmacol. 2008 Feb;153(4):636-45. Epub 2007 Oct 1. Review.

13.
14.

PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.

Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B.

J Clin Invest. 2005 Nov;115(11):3228-38.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk